Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2016 2
2017 2
2018 3
2019 2
2021 3
2022 5
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
Leroux-Roels I, Willems P, Waerlop G, Janssens Y, Tourneur J, De Boever F, Bruhwyler J, Alhatemi A, Jacobs B, Nicolas F, Leroux-Roels G, Le Vert A. Leroux-Roels I, et al. Among authors: le vert a. Lancet Infect Dis. 2023 Dec;23(12):1360-1369. doi: 10.1016/S1473-3099(23)00351-1. Epub 2023 Jul 27. Lancet Infect Dis. 2023. PMID: 37517422 Clinical Trial.
NF-κB Members Left Home: NF-κB-Independent Roles in Cancer.
Colomer C, Marruecos L, Vert A, Bigas A, Espinosa L. Colomer C, et al. Among authors: vert a. Biomedicines. 2017 May 25;5(2):26. doi: 10.3390/biomedicines5020026. Biomedicines. 2017. PMID: 28587092 Free PMC article. Review.
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
Withanage K, De Coster I, Cools N, Viviani S, Tourneur J, Chevandier M, Lambiel M, Willems P, Le Vert A, Nicolas F, Van Damme P. Withanage K, et al. Among authors: le vert a. J Infect Dis. 2022 Aug 12;226(1):119-127. doi: 10.1093/infdis/jiab532. J Infect Dis. 2022. PMID: 34653245 Free PMC article. Clinical Trial.
Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disease.
Godkin FE, Turner E, Demnati Y, Vert A, Roberts A, Swartz RH, McLaughlin PM, Weber KS, Thai V, Beyer KB, Cornish B, Abrahao A, Black SE, Masellis M, Zinman L, Beaton D, Binns MA, Chau V, Kwan D, Lim A, Munoz DP, Strother SC, Sunderland KM, Tan B, McIlroy WE, Van Ooteghem K. Godkin FE, et al. Among authors: vert a. J Neurol. 2022 May;269(5):2673-2686. doi: 10.1007/s00415-021-10831-z. Epub 2021 Oct 27. J Neurol. 2022. PMID: 34705114 Free PMC article.
p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis.
Solé L, Lobo-Jarne T, Álvarez-Villanueva D, Alonso-Marañón J, Guillén Y, Guix M, Sangrador I, Rozalén C, Vert A, Barbachano A, Lop J, Salido M, Bellosillo B, García-Romero R, Garrido M, González J, Martínez-Iniesta M, López-Arribillaga E, Salazar R, Montagut C, Torres F, Iglesias M, Celià-Terrassa T, Muñoz A, Villanueva A, Bigas A, Espinosa L. Solé L, et al. Among authors: vert a. Nat Commun. 2022 May 23;13(1):2866. doi: 10.1038/s41467-022-30382-9. Nat Commun. 2022. PMID: 35606354 Free PMC article.
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Leroux-Roels I, Waerlop G, Tourneur J, De Boever F, Maes C, Bruhwyler J, Guyon-Gellin D, Moris P, Del Campo J, Willems P, Leroux-Roels G, Le Vert A, Nicolas F. Leroux-Roels I, et al. Among authors: le vert a. Front Immunol. 2022 Apr 7;13:852904. doi: 10.3389/fimmu.2022.852904. eCollection 2022. Front Immunol. 2022. PMID: 35464450 Free PMC article. Clinical Trial.
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model.
Primard C, Monchâtre-Leroy E, Del Campo J, Valsesia S, Nikly E, Chevandier M, Boué F, Servat A, Wasniewski M, Picard-Meyer E, Courant T, Collin N, Salguero FJ, Le Vert A, Guyon-Gellin D, Nicolas F. Primard C, et al. Among authors: le vert a. Front Immunol. 2023 Jun 19;14:1188605. doi: 10.3389/fimmu.2023.1188605. eCollection 2023. Front Immunol. 2023. PMID: 37409116 Free PMC article.
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
Del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin ME, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F. Del Campo J, et al. Among authors: le vert a. NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019. NPJ Vaccines. 2019. PMID: 30701093 Free PMC article.
20 results